Validation of Euroscore II Cut-off at 12% for Active Infective Endocarditis

Authors

  • Komkrit Komuttarin Cardiothoracic Unit, Department of Surgery, Maharat Nakhon Ratchasima Hospital, Nakhon Ratchasima
  • Nisit Poolthananant Cardiothoracic Unit, Department of Surgery, Maharat Nakhon Ratchasima Hospital, Nakhon Ratchasima

Keywords:

Active infective endocarditis, Euroscore II, External validity

Abstract

Objective: Patients with infective endocarditis (IE) have a high risk of perioperative death. An accurate and reliable predictive score is crucial for decision making. The aim of this study is to externally validate Euroscore II, at a cut-off of 12%, in the prediction of hospital mortality.

Patients and Methods: Data were collected from medical records of patients who were diagnosed with active IE between June 1st 2017 and June 1st 2020. Preoperative Euroscore II was calculated. Patients were categorized into 2 groups according to Euroscore II: those with scores < 12 and ≥ 12. The discriminatory ability using the cut-off value was determined from observed perioperative mortality.

Results: There were 43 patients diagnosed with active IE. None had prosthetic IE. Most were male (56%). The mean age was 47.7 years. Large vegetation was found in 89%. Only one patient had ejection fraction < 40%. The most common clinical manifestation was heart failure (81%). Around four-fifths had single valvular involvement (82%). The most affected site was the aortic valve (44%). Median time from diagnosis to surgery was 7.5 days. Median duration of aortic cross-clamp time and cardiopulmonary bypass time were 83 mins and 99 mins respectively. The mean Euroscore II was 8.6%. There was 7% mortality (3/43). All deaths occurred in patients with Euroscore II ≥ 12. By using cut-off value of Euroscore II at 12%, the area under the receiver operating characteristic curve was 91.3% (95% CI 85.3 – 97.2%).

Conclusion: This study confirmed the validity of using Euroscore II ≥ 12% to help discriminate high-risk active IE patients. It might be accurate enough to help decision making for surgery in high-risk active IE patients in centers with similar circumstances.

Downloads

Download data is not yet available.

References

Komuttarin K, Himmunngan T. Predictive surgical outcome of EuroSCORE II for active endocarditis. J Health Sci 2019:28;711-20.

Delahaye F, Chu VH, Altclas J, et al. One-year outcome following biological or mechanical valve replacement for infective endocarditis. Int J Cardiol 2015;178:117-23.

Aithoussa M, Atmani N, Mounir R, et al. Early results for active infective endocarditis. Pan African Med J 2017;28:245. doi:10.11604/pamj.2017.28.245.13518.

Kurki TS, Järvinen O, Kataja MJ, et al. Performance of three preoperative risk indices; CABDEAL, EuroSCORE and Cleveland models in a prospective coronary bypass database. Eur J Cardiothorac Surg 2002;21:406-10.

Toumpoulis IK, Anagnostopoulos CE, DeRose JJ, Swistel DG. European system for cardiac operative risk evaluation predicts long-term survival in patients with coronary artery bypass grafting. Eur J Cardiothorac Surg 2004;25:51-8.

Toumpoulis IK, Anagnostopoulos CE, Toumpoulis SK, et al. EuroSCORE predicts long-term mortality after heart valve surgery. Ann Thorac Surg 2005;79:1902-8.

Parolari A, Pesce LL, Trezzi M, et al. EuroSCORE performance in valve surgery: a meta-analysis. Ann Thorac Surg 2010;89:787-93.

Gogbashian A, Sedrakyan A, Treasure T. EuroSCORE: a systematic review of international performance. Eur J Cardiothorac Surg 2004;25:695-700.

Chalmers J, Pullan M, Fabri B, et al. Validation of EuroSCORE II in a modern cohort of patients undergoing cardiac surgery. Eur J Cardiothorac Surg 2013;43:688-94.

Rabbani MS, Qadir I, Ahmed Y, Gul M, Sharif H. Heart valve surgery: EuroSCORE vs. EuroSCORE II vs. Society of Thoracic Surgeons score. Heart Int 2014;9:53-8.

Biancari F, Vasques F, Mikkola R, et al. Validation of EuroSCORE II in patients undergoing coronary artery bypass surgery. Ann Thorac Surg 2012;93:1930-5.

Howell NJ, Head SJ, Freemantle N, et al. The new EuroSCORE II does not improve prediction of mortality in high-risk patients undergoing cardiac surgery: a collaborative analysis of two European centres. Eur J Cardiothorac Surg 2013;44:1006-11.

Paparella D, Guida P, Di Eusanio G, et al. Risk stratification for in-hospital mortality after cardiac surgery: external validation of EuroSCORE II in a prospective regional registry. Eur J Cardiothorac Surg. 2014;46:840-8.

Kouchoukos NT, Blackstone EH, Hanley FL, Kirklin JK. In Kirklin/Barratt-Boyes cardiac surgery, 4th ed. Philadelphia: Elsevier Saunders 2013.

Koshy J, Engel M, Carrara H, et al. Long term outcome and EuroSCORE II validation in native valve surgery for active infective endocarditis in a South African cohort. SA Heart 2018;15:116-126.

Habib G, Hoen B, Tornos P, et al. Guidelines on the prevention, diagnosis, and

treatment of infective endocarditis(new version 2009): the Task Force on the

Prevention, Diagnosis, and Treatment of Infective Endocarditis of the European Society of Cardiology (ESC). Endorsed by the European Society of Clinical Microbiology and Infectious Diseases(ESCMID) and the International Society of Chemotherapy (ISC) for Infection and Cancer. Eur Heart J 2009;30:2369-413.

Delahaye F. Is early surgery beneficial in infective endocarditis? A systemic review. Arch Cardiovasc Dis 2011;104:35-44.

Mourvillier B, Trouillet JL, Timsit JF, et al. Infective endocarditis in the intensive care unit: clinical spectrum and prognostic factors in 228 consecutive patients. Intensive Care Med 2004;30:2046-52.

Revilla A, López J, Vilacosta I, et al. Clinical and prognostic profile of patients with infective endocarditis who need urgent surgery. Eur Heart J 2007;28:65-71.

David TE, Gavra G, Feindel CM, Regesta T, Armstrong S, Maganti MD. Surgical treatment of active infective endocarditis: a continued challenge. J Thorac Cardiovasc Surg 2007;133:144-9.

Mullany CJ, Chua YL, Schaff HV, et al. Early and late survival after surgical treatment of culture-positive active endocarditis. Mayo ClinProc 1995;70:517-25.

Hanai M, Hashimoto K, Mashiko K, et al. Active infective endocarditis: management and risk analysis of hospital death from 24 years' experience. Circ J 2008;72:2062-8.

Fayad G, Leroy G, Devos P, et al. Characteristics and prognosis of patients requiring valve surgery during active infective endocarditis. J Heart Valve Dis 2011;20:223-8.

d'Udekem Y, David TE, Feindel CM, et al. Long-term results of surgery for active infective endocarditis. Eur J Cardiothorac Surg 1997;11:46-52.

Spiliopoulos K, Giamouzis G, Haschemi A, et al. Surgical management of infective endocarditis: early and long-term mortality analysis. single-center experience and brief literature review. Hellenic J Cardiol 2014;55:462-74.

Funakoshi S, Kaji S, Yamamuro A, et al. Impact of early surgery in the active phase on long-term outcomes in left-sided native valve infective endocarditis. J Thorac Cardiovasc Surg 2011;142:836-42.

Siregar S, Groenwold RH, de Heer F, et al. Performance of the original EuroSCORE. Eur J CardiothoracSurg 2012;41:746-54.

Stavridis G, Panaretos D, Kadda O, Panagiotakos DB. Validation of the EuroSCORE II in a Greek Cardiac Surgical Population: a prospective study. Open Cardiovasc Med J 2017;11:94-101.

Kartal H, Sicim H, Demirtas E, et al. Evaluatıon of effectıveness of Euroscore 2 in patıents undergoıng isolated coronary artery bypass and isolated mıtral valve replacement surgery. EJMI 2020;4:442–7.

Nashef SA, Roques F, Sharples LD, et al. EuroSCORE II. Eur J Cardiothorac Surg 2012;41:734-44.

Patrat-Delon S, Rouxel A, Gacouin A, et al. EuroSCORE II underestimates mortality after cardiac surgery for infective endocarditis. Eur J Cardiothorac Surg 2016;49:944-51.

Madeira S, Rodrigues K, Tralhão A, et al. Assessment of perioperative mortality risk in patients with infective endocarditis undergoing cardiac surgery: performance of the EuroSCORE I and II logistic models. Interact Cardiovasc Thorac Surg 2014;18:539-43.

Downloads

Published

2021-12-30 — Updated on 2022-01-25

Versions

How to Cite

1.
Komuttarin K, Poolthananant N. Validation of Euroscore II Cut-off at 12% for Active Infective Endocarditis. Thai J Surg [Internet]. 2022 Jan. 25 [cited 2022 Oct. 5];42(4):167-73. Available from: https://he02.tci-thaijo.org/index.php/ThaiJSurg/article/view/250968

Issue

Section

Original Articles